Key Points
- CEO Vlad Vitoc bought 72,700 shares of MAIA Biotechnology at an average price of $1.39, a purchase worth about $101,053. After the transaction, he owned 976,121 shares, lifting his position by 8.05%.
- MAIA Biotechnology shares were trading up 3.8% at $1.35. The company has a market cap of about $82.08 million and a 52-week range of $0.87 to $3.19.
- The company recently reported a quarterly loss of $0.14 per share, which beat analyst expectations of a $0.18 loss. Analysts currently expect MAIA to post a full-year loss of $0.52 per share.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith bought 75,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was acquired at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the acquisition, the director directly owned 1,519,178 shares in the company, valued at $2,035,698.52. The trade was a 5.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
MAIA Biotechnology Price Performance
MAIA opened at $1.35 on Wednesday. MAIA Biotechnology, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.19. The firm has a market capitalization of $82.08 million, a PE ratio of -2.01 and a beta of 0.23. The company's 50-day moving average is $1.32 and its 200 day moving average is $1.52.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, analysts expect that MAIA Biotechnology, Inc. will post -0.52 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Corsair Capital Management L.P. bought a new position in shares of MAIA Biotechnology during the 1st quarter valued at approximately $140,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the 4th quarter valued at approximately $120,000. Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company's stock valued at $454,000 after acquiring an additional 25,684 shares during the period. Centric Wealth Management grew its position in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company's stock valued at $897,000 after acquiring an additional 11,500 shares during the period. Finally, Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology during the 4th quarter valued at approximately $35,000. 5.65% of the stock is owned by institutional investors.
MAIA Biotechnology Company Profile
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
